Castle biosciences stock.

11/08/2023 - 01:00 PM. FRIENDSWOOD, Texas -- (BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this …

Castle biosciences stock. Things To Know About Castle biosciences stock.

Dec 1, 2023 · View Castle Biosciences, Inc CSTL investment & stock information. Get the latest Castle Biosciences, Inc CSTL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Belgium, a country known for its rich history, stunning architecture, and vibrant culture, offers a plethora of attractions for visitors to explore. From medieval castles to modern art galleries, Belgium has something for everyone.Castle Biosciences Stock Forecast · Over the next 52 weeks, Castle Biosciences has on average historically fallen by 6.5% based on the past 3 years of stock ...Castle Biosciences is a commercial-stage diagnostics company that provides testing services for dermatological cancers. …In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.

Insiders trading at Castle Biosciences. Over the last 4 years, insiders at Castle Biosciences have traded over $369,408,068 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold, and Joseph C. Iii Cook.On average, Castle …559.98%. Get the latest Castle Biosciences Inc (CSTL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...Castle Biosciences (CSTL) In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences, with a price target of $38.00 . The company’s shares closed last ...

Dec 1, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma. By providing your email address below, you are providing consent to Castle Biosciences to send you the requested Investor Email Alert updates. * Required. Email Address*. Investor Alert Options*. News. Events & Presentations. Quarterly Reports. Annual Reports. SEC Filings.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma.The estimated Net Worth of Mara G. Aspinall is at least $2.42 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,626,983 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...Castle Biosciences. Sales (Current Employee) - Friendswood, TX - March 16, 2021. Castle Biosciences is a very culture & mission driven company that genuinely cares for their employees. Working at Castle for almost 5 years now, I can confidently say that I am a valued employee, who is respected as an individual in a company of 240+ employees.Europe PMC is an archive of life sciences journal literature.

Castle Biosciences had a GAAP loss of 70 cents a share, approximately 20 cents a share above expectations. Revenues rose 44% on a year-to-year basis to $50.1 million, almost $6 million over the ...

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive …

Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...... stock price multiplied by the number of shares outstanding. Castle Biosciences net worth as of November 17, 2023 is $0.53B. Compare CSTL With Other Stocks ...The estimated Net Worth of Mara G. Aspinall is at least 2.53 百万$ dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over 1,731,228$ and over the last 8 years she sold CSTL stock worth over 494,800$. In addition, she makes 302,714$ as Independent Director at Castle Biosciences.S hares of Castle Biosciences (NASDAQ: CSTL) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is ...The estimated Net Worth of Mara G. Aspinall is at least $2.81 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $2,014,618 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.

Mar 1, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago. Ms. Aspinall CSTL stock SEC Form 4 insiders trading. Mara has made over 10 trades of the Castle Biosciences stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 3,825 units of CSTL stock worth $68,774 on 2 June 2023.. The largest trade she's ever made was buying 6,000 units of Castle Biosciences …The estimated Net Worth of Mara G. Aspinall is at least $2.59 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,789,913 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Shares of Castle Biosciences, Inc. have returned +1.9% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it ...2.64%. $8.71B. CSTL | Complete Castle Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Forecasts are adjusted once a day taking into account the price change of the previous day. To date, analysts have a $33 target price for Castle Biosciences stock stock. Today 200 Day Moving Average is the resistance level (20.43 $). 50 Day Moving Average is the resistance level (17.26 $). 2023.Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,041 on 2 June 2023.. The largest trade he's ever made was exercising 3,825 units of Castle Biosciences …

... stock price multiplied by the number of shares outstanding. Castle Biosciences net worth as of November 17, 2023 is $0.53B. Compare CSTL With Other Stocks ...These 4 analysts have an average price target of $38.75 versus the current price of Castle Biosciences at $22.02, implying upside. Below is a summary of how these 4 analysts rated Castle ...Leadership: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Patents with Castle Biosciences. No other potential conflicts of interest were reported. OPTIONS & TOOLS. Export Citation: Track Citation: Add To Favorites: Rights & Permissions; COMPANION …Castle Biosciences Inc. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians …Forecst.com predicts future values using technical analysis of a large number of analytical parameters. CSTL stock returns are also predicted based on historical data. According to our research, CSTL stock is a bad long-term investment. CSTL share price has been in a bear cycle for the past year. Castle Biosciences, Inc. stock trend is …At closing, Castle will pay $30 million in initial consideration to Cernostics security holders, which may consist entirely of cash or $20 million in cash and $10 million in common stock of Castle ...Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.Castle Biosciences, Inc. (NASDAQ:NASDAQ:CSTL) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ETCompany ParticipantsCamilla Zuckero - Vice...PURPOSE KRAS is the most mutated proto-oncogene that has been identified in cancer, and treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRASG12C mutation has attracted special interest because it is now considered potentially druggable with recently developed covalent small-molecule KRASG12C inhibitors. …Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47.

The shares are expected to begin trading on The Nasdaq Global Market on July 25, 2019 under the symbol “CSTL.” All of the common stock in the offering is being ...

David Kabakoff CSTL stock SEC Form 4 insiders trading. David has made over 21 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 30,000 units of CSTL stock worth $2,252,100 on 17 June 2021.. The largest trade he's ever made was selling 250,000 units of Castle …

Kim Caple CSTL stock SEC Form 4 insiders trading. Kim has made over 3 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Kim exercised 440 units of CSTL stock worth $8,642 on 14 July 2023.. The largest trade Kim's ever made was exercising 3,825 units of Castle Biosciences …On November 2, 2023, Castle Biosciences (NASDAQ:CSTL) released its Q3 2023 financial report, showcasing impressive results. The company reported a loss of $ (0.26) per share, surpassing the analyst consensus estimate of $ (0.76) by an impressive 65.79 percent. This marks a remarkable 66.23 percent increase in losses compared to the same period ...Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. At closing, Castle will pay $30 million in initial consideration to Cernostics security holders, which may consist entirely of cash or $20 million in cash and $10 million in common stock of Castle ...Dec 1, 2023 · CSTL Earnings Date and Information. Castle Biosciences last released its earnings results on November 2nd, 2023. The reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.66. The company earned $61.49 million during the quarter, compared to the consensus estimate of $44.94 million. The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement ...7 Nis 2021 ... Product details ... Do you want to earn up to a 1117163% annual return on your money by two trades per day on Castle Biosciences Inc CSTL Stock?David Kabakoff CSTL stock SEC Form 4 insiders trading. David has made over 21 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 30,000 units of CSTL stock worth $2,252,100 on 17 June 2021.. The largest trade he's ever made was selling 250,000 units of Castle …Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...559.98%. Get the latest Castle Biosciences Inc (CSTL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...The estimated Net Worth of Mara G. Aspinall is at least $2.42 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,626,983 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Instagram:https://instagram. excess savingspropetrosell iphone with cracked screenbest company to buy gold and silver from Nov 24, 2023 gun and trophy insurancegym liability insurance Track Castle Biosciences Inc (CSTL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors best virtual reality stocks 2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%)...Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe …